Breaking News Instant updates and real-time market news.

MDCO

The Medicines Co.

$42.56

-0.83 (-1.91%)

17:12
05/19/17
05/19
17:12
05/19/17
17:12

Court preliminarily approves settlement in The Medicines Co.'s cangrelor case

On May 12, the United States District Court for the District of New Jersey issued an order preliminarily approving a proposed settlement by and among The Medicines Company, the plaintiffs, and all named individual defendants in the shareholder derivative action Case No. 2:17-cv-01597 related to the company's clinical trial of cangrelor. The proposed settlement requires the company to implement certain corporate governance measures and pay certain attorneys' fees and expenses to plaintiff's counsel in an amount to be determined by the court. A hearing to determine whether the court should issue an order of final approval of the settlement has been scheduled for September 21, 2017 at 10:30 a.m. in Courtroom MLK 5B of the United States District Court for the District of New Jersey, Martin Luther King Building & United States Courthouse, 50 Walnut Street, Newark, New Jersey 07101 to determine whether the terms and conditions of the settlement are adequate, fair and reasonable. Pursuant to the court's order, any objections to the settlement must be filed in writing with the court by no later than August 17, 2017.

  • 22

    May

  • 06

    Jun

MDCO The Medicines Co.
$42.56

-0.83 (-1.91%)

03/17/17
JPMS
03/17/17
NO CHANGE
JPMS
Overweight
Amgen data do not justify Medicines selloff, says JPMorgan
JPMorgan analyst Jessica Fye believes today's cholesterol data from Amgen (AMGN) do not justify the downward move in shares of The Medicines Co. (MDCO). The analyst sees a "clear clinical benefit" from Amgen's Repatha, which she thinks support the likelihood of clinical success and value for Medicines' inclisiran. The analyst remains comfortable with her 70% probability of success and $1.6B peak sales forecast for inclisiran. Fye keeps an Overweight rating on Medicines and believes the 18% selloff today is overdone.
04/13/17
JEFF
04/13/17
NO CHANGE
Target $62
JEFF
Buy
Medicines Co. open to spinoff of infectious disease unit, says Jefferies
After spending time with management as the company evaluates all strategic options including a sale, Jefferies analyst Biren Amin says The Medicines Company believes there is more than one form for a takeover. In addition to the entire organization potentially being acquired, management spoke of a scenario whereby an acquirer may not want the infectious disease business, Amin telsl investors in a research note. Under such a case, the company would be prepared to spin-off as a standalone organization upon a sale of inclisiran, the analyst adds. He believes this option leaves room to negotiate on the value of inclisiran versus simply paying a premium over the current share price. Amin keeps a Buy rating on Medicines Co. with a $62 price target.
04/19/17
COWN
04/19/17
NO CHANGE
Target $61
COWN
Outperform
The Medicines Co. price target raised to $61 from $39 at Cowen
Cowen analyst Chris Shibutani raised his price target on The Medicines Company to $61 from $39 following a cardiologist survey suggesting the company's Inclisiran will contend for patient share assuming pivotal data demonstrates similar safety and efficacy to monoclonal antibodies. Shibutani reiterated his Outperform rating on The Medicines Company shares.
04/21/17
JEFF
04/21/17
NO CHANGE
Target $62
JEFF
Buy
The Medicines Co. suggesting several parties interested in deal, says Jefferies
Jefferies analyst Biren Amin said feedback he's received from management at The Medicines Co. suggests that talks about the company's strategic process began in January and that there are "several interested parties" involved. Management added that they will stay open to discussions until "significant" patient enrollment has occurred in their Phase 3 trail, Amin added. The analyst, who thinks a 13-15 month timeframe is a reasonable one to expect for the process to come to a conclusion, keeps a Buy rating and $62 price target on Medicines Co. shares.

TODAY'S FREE FLY STORIES

WPG

Washington Prime

$9.11

-0.02 (-0.22%)

16:36
07/26/17
07/26
16:36
07/26/17
16:36
Earnings
Washington Prime reports Q2 EPS 72c vs. 10c a year ago »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CSGP

CoStar Group

$281.32

-0.65 (-0.23%)

16:36
07/26/17
07/26
16:36
07/26/17
16:36
Earnings
CoStar Group reports Q2 EPS 86c, consensus 63c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

TBK

Triumph Bancorp

$28.80

0.2 (0.70%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Conference/Events
Triumph Bancorp to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 18

    Sep

ORLY

O'Reilly Automotive

$187.43

0.58 (0.31%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
O'Reilly Automotive reports Q2 EPS $3.10, consensus $2.89 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
On Assignment sees Q3 adjusted EPS 73c-76c, consensus 80c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CNO

CNO Financial

$21.75

-0.52 (-2.34%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
CNO Financial reports Q2 EPS 48c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BWLD

Buffalo Wild Wings

$122.65

-1.05 (-0.85%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Buffalo Wild Wings »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 11

    Sep

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Hot Stocks
Whirlpool increases share repurchase authorization to $2.35B »

"Our strong free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Earnings
Breaking Earnings news story on Duke Realty »

Duke Realty sees 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BXS

BancorpSouth

$30.25

-1 (-3.20%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
BancorpSouth raises quarterly dividend 12% to 14c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 18

    Sep

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Duke Realty reports Q2 core FFO 32c, consensus 31c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
On Assignment reports Q2 EPS 62c, consensus 72c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ANIK

Anika Therapeutics

$47.99

-0.27 (-0.56%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Anika Therapeutics reports Q2 EPS 76c, consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

UVSP

Univest

$30.00

-0.3 (-0.99%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Breaking Earnings news story on Univest »

Univest reports Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
Realty Income sees FY17 EPS $1.15-$1.20, consensus $1.22 »

Company estimates FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Whirlpool reports Q2 EPS $3.35, consensus $3.54 »

Reports Q2 revenue $5.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMO

Capstead Mortgage

$9.99

-0.06 (-0.60%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Capstead Mortgage reports Q2 EPS 14c, consensus 20c »

Book value per common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BPI

Bridgepoint Education

$12.29

-0.98 (-7.39%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Bridgepoint Education reports Q2 EPS 21c, consensus 23c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 10

    Aug

BDGE

Bridge Bancorp

$32.90

-0.7 (-2.08%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Breaking Earnings news story on Bridge Bancorp »

Bridge Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

QEP

QEP Resources

$9.27

0.07 (0.76%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
QEP Resources reports Q2 adjusted EPS (12c), consensus (20c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
Breaking Earnings news story on Monolithic Power »

Monolithic Power sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

UDR

UDR, Inc.

$39.19

0.51 (1.32%)

16:31
07/26/17
07/26
16:31
07/26/17
16:31
Earnings
UDR, Inc. backs FY17 EPS view of 31c-36c, consensus 28c »

Reaffirmed FFO per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

FFIV

F5 Networks

$128.20

0.18 (0.14%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
F5 Networks sees Q4 non-GAAP EPS $2.20-$2.23, consensus $2.24 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 05

    Sep

MPWR

Monolithic Power

$106.79

1.86 (1.77%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Monolithic Power reports Q2 EPS 68c, consensus 67c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

  • 10

    Aug

  • 15

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:30
07/26/17
07/26
16:30
07/26/17
16:30
Earnings
Realty Income reports Q2 EPS 30c, consensus 32c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.